Table 1 Demographical characteristics of the patients included in the study at the onset of natalizumab treatment.
Gender | N |
Males | 64 |
Females | 122 |
Age (years, med (P25-P75)) | 37.0 (27.0–46.5) |
Age at disease onset (years, med (P25-P75)) | 27.0 (19.0–38.0) |
Disease duration at natalizumab onset (months, med (P25-P75)) | 92.0 (24.0–226.0) |
MS type | N |
RR | 169 |
SP | 17 |
EDSS (med (P25-P75)) | 3.0 (1.5–5.5) |
Relapses 2 years before (med (P25-P75)) | 2.0 (1.0–4.5) |
Treatment naïve (N) | 28 |
Last treatment before natalizumab onset | N |
Glatiramer acetate | 54 |
Interferon beta | 93 |
Mitoxantrone | 7 |
Cyclophosphamide | 2 |
Fingolimod | 1 |
Teriflunomide | 1 |
Duration of the last treatment (months, med (P25-P75)) | 25.0 (11.0–49.0) |
Number of previous treatments before natalizumab onset | N |
1 | 86 |
2 | 49 |
3 | 15 |
4 | 6 |
5 | 2 |
Months treated before natalizumab onset (med (P25-P75))* | 49.0 (21.0–81.0) |
Patients receiving previous immunosuppressant treatment (N) | 19 |
Months under immunosuppressant treatment (med (P25-P75))** | 15.0 (3.0–24.0) |
Months since disease onset until first treatment (med (P25-P75)) | 32.0 (13.0–83.0) |
